HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of Merck & Co.

By FierceBiotech · May 12, 2026 · via FierceBiotech
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Partner Therapeutics secures FDA approval for Bizengri
PipelinePharmaceutical Technology ↗
Partner Therapeutics secures FDA approval for Bizengri
Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or met…
May 12, 2026
BMS’ Sotyktu secures EC approval for psoriatic arthritis
PipelinePharmaceutical Technology ↗
BMS’ Sotyktu secures EC approval for psoriatic arthritis
BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …
May 11, 2026
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
PipelineFiercePharma ↗
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
May 10, 2026